GSK plc (NYSE/LSE: GSK) features a broad global ownership structure dominated by major institutional asset management firms and international investment funds. Leading institutional stakeholders include Wellington Management Group, BlackRock, The Vanguard Group, and UBS Asset Management, alongside widespread retail investor participation. These major financial institutions hold significant voting rights and equity proportions, closely monitoring pharmaceutical research pipelines, vaccine sales, and legal developments.